TRACERx EVO aims to accelerate our understanding of lung cancer evolution, drug resistance, metastasis, immune evasion and their combined impact on the patient's metabolism and body composition. Participants will receive standard of care anti-cancer therapies for their lung cancer as dictated by their treating team (for example: systemic therapies, radiotherapy and surgery, as per local and national guidelines). Participants who consent to the study will be approached for cancer tissue samples, blood and other samples (such as urine, stool, saliva, and nasal epithelial samples). Data on the participant’s demographics, treatment plans, imaging results and outcomes will also be collected. Using the collected tissue, blood and other samples, we hope to build a well curated data set to better understand how cancers spread, why they become resistant to treatments, and why severe weight loss is seen in patients with cancer. Multiple types of analyses will be performed, including, but not limited to, genetic, metabolism, immune cell analyses, as well as mouse model and cell line analyses. By building on the work performed in the original study, TRACERx, we hope that TRACERx EVO will further improve our understanding of lung cancer, and lead to improvements in patient care in the future.